I'm saying that the strategy has a variety. To ensure that we have everyone at the table and that we can all focus on the common signal, we're talking about how to reduce the harms related to.... And that is a very clear element throughout: you'll see a lot of recommendations in here that are consistent with the term “harm reduction” that you're referring to. But this is focused on specific actions.
Second, these are controlled legal substances. This in fact underscores the challenge of looking at this through a lens of “legal” or “illegal”. These are highly controlled, presumably difficult-to-access substances, and yet we have a crisis on our hands.
The reduction of risk is by far maximally advantaged by looking first of all at how these drugs are accessed. It is largely through prescribers and through areas in which we can see that there might be some diversion on the illicit side.
This speaks to a very comprehensive strategy, focusing not only on one particular element, as I mentioned with Dr. Fry, I think, but starting with prevention and education of the prescriber and going straight on through the supply chain. I think that everybody who sees and reads these recommendations will see that concept of reducing harm throughout.